Expected Revenue Growth:
The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %.
Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.
COVID-19 Impact on the global human organoids market
The COVID-19 pandemic has significantly affected the human organoids market. The market is facing challenges in the manufacturing and supply chain, such as delivering products to end users in a timely manner as well as attending to an uneven demand for the products and services in the sector. In addition, a dearth of skilled lab professionals to conduct/study diagnostic tests, limited operations in most of the industries, inadequate funding for research and academic institutes, temporary closure of major academic institutes, disrupted supply chain, and challenges in providing essential/post-sales services due to lockdowns have led to the reduced supply of human organoid products to end users.
Download PDF Brochure@
In April 2020, according to Fortis Organ Retrieval & Transplant, due to COVID-19 restrictions for one month, more than 2,000 blind individuals faced difficulties. The pandemic has adversely impacted organ donation and transplantation in countries that have experienced high rates of infection, including the US, France, and the UK, all reporting >50% reductions in transplant activity. Australia has experienced a significantly lower incidence of COVID-19. Despite this, the impact on organ transplantation has been significant.
Similarly, in March 2020, organ transplant centers in Wuhan (China) halted all transplant surgeries. A suspension on living donor transplants, pancreas transplants, and renal transplants was first considered in other less affected regions; however, lifesaving urgent transplant surgeries still proceeded in most centers. Statistics showed a drastic 90.6% and 51.1% reduction in deceased donor transplants in France and the US, respectively, which is mostly driven by kidney transplants.
The total amount of organ transplants reduced from 100~150 to 40 transplants per month in the Netherlands. Despite the challenging situation, industries are gradually recovering from the impact, and as supply and distribution channels are beginning to resume, business operations have started to rise at a slow and steady rate. Thus, the pandemic is not estimated to have long-term effects on the fundamental growth drivers or end users in the human organoids market.
Kidney estimated to be the growing market
The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures), and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.
Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally
Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.
Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).
Request Sample Pages@
# In 2020, BIOIVT (US) partnered with upcyte technologies GmbH (Germany) as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
# In 2019, Hurel and Cyprotex came into partnership which enabled Cyprotex to independently validate the HµREL multi-donor coculture model for clearance studies.
# In 2019, Organovo collaborated with MCRI and Leiden University Medical Center to develop stem cell-based bioprinted tissue treatment for kidney diseases.
# In 2018, Absolute Antibody merged with Kerafast to increase access to unique reagents.